ArticleJournal for immunotherapy of cancer2024

A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.

Pénélope Desroys du Roure et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.